Related references
Note: Only part of the references are listed.SGLT2 inhibitors and the autonomic nervous system in diabetes: A promising challenge to better understand multiple target improvement
Vincenza Spallone et al.
DIABETES & METABOLISM (2021)
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and-2 studies
Moshe Phillip et al.
DIABETES OBESITY & METABOLISM (2021)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Role of NLRP3 Inflammasome Activation in Obesity-Mediated Metabolic Disorders
Kaiser Wani et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)
Adenosine 5′-monophosphate-activated protein kinase ameliorates bovine adipocyte oxidative stress by inducing antioxidant responses and autophagy
Qiushi Xu et al.
JOURNAL OF DAIRY SCIENCE (2021)
Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial
Eiichi Araki et al.
DIABETES OBESITY & METABOLISM (2020)
The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition
Megan E. Capozzi et al.
DIABETES (2020)
Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice
Jae-Hyung Park et al.
JOURNAL OF PINEAL RESEARCH (2020)
Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay
Huan Chen et al.
CARDIOVASCULAR DRUGS AND THERAPY (2020)
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Mark C. Petrie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Dapagliflozin restores insulin and growth hormone secretion in obese mice
Zhengxiang Huang et al.
JOURNAL OF ENDOCRINOLOGY (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
COVID-19: Proposing a Ketone-Based Metabolic Therapy as a Treatment to Blunt the Cytokine Storm
Patrick C. Bradshaw et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2020)
Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression
Giovanni Musso et al.
PLOS MEDICINE (2020)
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
David C Wheeler et al.
Lancet Diabetes & Endocrinology (2020)
Role of mitochondria in pathogenesis of type 2 diabetes mellitus
Pankaj Prasun
JOURNAL OF DIABETES AND METABOLIC DISORDERS (2020)
Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats
Rachel J. Perry et al.
NATURE COMMUNICATIONS (2019)
Silibinin inhibits in vitro ketosis by regulating HMGCS2 and NF-kB: elucidation of signaling molecule relationship under ketotic conditions
Dong Young Kang et al.
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Substrate metabolism, hormone and cytokine levels and adipose tissue signalling in individuals with type 1 diabetes after insulin withdrawal and subsequent insulin therapy to model the initiating steps of ketoacidosis
Thomas S. Voss et al.
DIABETOLOGIA (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes
Yochai Birnbaum et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
TBK1 at the Crossroads of Inflammation and Energy Homeostasis in Adipose Tissue
Peng Zhao et al.
CELL (2018)
Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in adipocytes
Shigeki Nishitani et al.
SCIENTIFIC REPORTS (2018)
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
F. Bonnet et al.
DIABETES & METABOLISM (2018)
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Julio Rosenstock et al.
DIABETES CARE (2018)
Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis
Xiaofang Yu et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2018)
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly
Marino Quarella et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
Vance B. Matthews et al.
JOURNAL OF HYPERTENSION (2017)
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
Michael Fralick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
Satish K. Garg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dapagliflozin suppresses glucagon signaling in rodent models of diabetes
May-yun Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes
Li Tang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2017)
Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells
A. Solini et al.
DIABETES & METABOLISM (2017)
Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study
Neha S. Patel et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2017)
Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives
Hongyu Qiu et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2017)
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor
Yumei Ye et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
Combined Insulin Deficiency and Endotoxin Exposure Stimulate Lipid Mobilization and Alter Adipose Tissue Signaling in an Experimental Model of Ketoacidosis in Subjects With Type 1 Diabetes: A Randomized Controlled Crossover Trial
Mads Svart et al.
DIABETES (2016)
Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes
Anne L. Peters et al.
DIABETES CARE (2016)
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
Giuseppe Daniele et al.
DIABETES CARE (2016)
Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients
Aki Okamoto et al.
DRUGS IN R&D (2016)
β-Hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation
Ha Ram Bae et al.
ONCOTARGET (2016)
Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells
Morten Gram Pedersen et al.
SCIENTIFIC REPORTS (2016)
The Regulation of NF-κB Subunits by Phosphorylation
Frank Christian et al.
CELLS (2016)
Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
Robert R. Henry et al.
DIABETES CARE (2015)
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
Julio Rosenstock et al.
DIABETES CARE (2015)
The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
Yun-Hee Youm et al.
NATURE MEDICINE (2015)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
Caroline Bonner et al.
NATURE MEDICINE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
MCP-1 and IL-1β expression in the myocardia of two young patients with Type 1 diabetes mellitus and fatal diabetic ketoacidosis
Jianli Niu et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2014)
The association of oxidative stress and pro-inflammatory cytokines in diabetic patients with hyperglycemic crisis
Juan Li et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages
Kenneth R. Feingold et al.
JOURNAL OF LIPID RESEARCH (2014)
BHBA Suppresses LPS-Induced Inflammation in BV-2 Cells by Inhibiting NF-κB Activation
Shou-Peng Fu et al.
MEDIATORS OF INFLAMMATION (2014)
Diabetic Ketoacidosis Elicits Systemic Inflammation Associated with Cerebrovascular Endothelial Cell Dysfunction
Taylor E. Close et al.
MICROCIRCULATION (2013)
Anti-Inflammatory Effects of Nicotinic Acid in Human Monocytes Are Mediated by GPR109A Dependent Mechanisms
Janet E. Digby et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Effects of high fat diet on GPR109A and GPR81 gene expression
Desiree Wanders et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
GPR109A as an Anti-Inflammatory Receptor in Retinal Pigment Epithelial Cells and Its Relevance to Diabetic Retinopathy
Deeksha Gambhir et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2012)
The Nfkb1 and Nfkb2 Proteins p105 and p100 Function as the Core of High-Molecular-Weight Heterogeneous Complexes
Olga V. Savinova et al.
MOLECULAR CELL (2009)
Neuroinflammatory response of the choroid plexus epithelium in fatal diabetic ketoacidosis
William H. Hoffman et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2007)
(D)-β-hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G
AKP Taggart et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Hyperketonemia increases tumor necrosis factor-α secretion in cultured U937 monocytes and type 1 diabetic patients and is apparently mediated by oxidative stress and cAMP deficiency
SK Jain et al.
DIABETES (2002)
Share Paper
